Redmile Group, LLC - Q1 2018 holdings

$2.59 Billion is the total value of Redmile Group, LLC's 64 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 42.9% .

 Value Shares↓ Weighting
ARRY SellARRAY BIOPHARMA INC$281,103,000
+14.9%
17,224,428
-9.9%
10.86%
+2.1%
ATRA BuyATARA BIOTHERAPEUTICS INC$165,205,000
+224.1%
4,236,017
+50.4%
6.38%
+187.9%
FOLD BuyAMICUS THERAPEUTICS INC$161,509,000
+11.9%
10,738,658
+7.1%
6.24%
-0.6%
IMGN SellIMMUNOGEN INC$102,070,000
+46.0%
9,702,482
-11.0%
3.94%
+29.7%
XNCR BuyXENCOR INC$96,066,000
+224.4%
3,204,343
+137.2%
3.71%
+188.3%
WVE BuyWAVE LIFE SCIENCES LTD$89,728,000
+15.7%
2,237,607
+1.3%
3.46%
+2.8%
ALDR  ALDER BIOPHARMACEUTICALS INC$82,623,000
+10.9%
6,505,7660.0%3.19%
-1.5%
AVXS NewAVEXIS INC$78,708,000636,900
+100.0%
3.04%
PBYI BuyPUMA BIOTECHNOLOGY INC$74,556,000
-17.4%
1,095,612
+19.9%
2.88%
-26.7%
WCG BuyWELLCARE HEALTH PLANS INC$66,281,000
+128.3%
342,309
+137.1%
2.56%
+102.8%
ABT BuyABBOTT LABS$65,678,000
+28.3%
1,096,100
+22.2%
2.54%
+14.0%
FATE BuyFATE THERAPEUTICS INC$64,962,000
+94.5%
6,655,962
+21.8%
2.51%
+72.8%
RGNX BuyREGENXBIO INC$63,610,000
+34.2%
2,130,972
+49.5%
2.46%
+19.2%
PEN SellPENUMBRA INC$63,270,000
+8.9%
547,079
-11.4%
2.44%
-3.2%
CNC BuyCENTENE CORP DEL$59,826,000
+9.5%
559,800
+3.4%
2.31%
-2.7%
ANAB BuyANAPTYSBIO INC$54,449,000
+135.2%
523,150
+127.6%
2.10%
+109.0%
SYNH NewSYNEOS HEALTH INCcl a$54,177,0001,526,104
+100.0%
2.09%
ICUI BuyICU MED INC$48,832,000
+61.5%
193,472
+38.2%
1.89%
+43.5%
INSM SellINSMED INC$48,786,000
-30.4%
2,166,362
-3.7%
1.88%
-38.2%
IRTC SellIRHYTHM TECHNOLOGIES INC$45,946,000
+0.6%
729,874
-10.4%
1.77%
-10.6%
LIVN SellLIVANOVA PLC$45,868,000
-6.8%
518,288
-15.8%
1.77%
-17.2%
BLUE BuyBLUEBIRD BIO INC$45,607,000
-1.4%
267,100
+2.8%
1.76%
-12.5%
ALXN NewALEXION PHARMACEUTICALS INC$45,119,000404,800
+100.0%
1.74%
TFX BuyTELEFLEX INC$45,026,000
+4.9%
176,586
+2.4%
1.74%
-6.8%
BOLD BuyAUDENTES THERAPEUTICS INC$39,321,000
+35.4%
1,308,526
+40.8%
1.52%
+20.2%
CBAY BuyCYMABAY THERAPEUTICS INC$38,393,000
+108.4%
2,955,565
+47.6%
1.48%
+85.1%
GLYC BuyGLYCOMIMETICS INC$37,041,000
+14.3%
2,282,268
+18.2%
1.43%
+1.5%
EPZM BuyEPIZYME INC$35,713,000
+47.8%
2,011,989
+4.5%
1.38%
+31.2%
UNH SellUNITEDHEALTH GROUP INC$31,120,000
-5.0%
145,420
-2.2%
1.20%
-15.6%
OXFD BuyOXFORD IMMUNOTEC GLOBAL PLC$30,748,000
-5.1%
2,469,687
+6.5%
1.19%
-15.7%
JNCE BuyJOUNCE THERAPEUTICS INC$26,426,000
+111.4%
1,182,393
+20.6%
1.02%
+87.8%
NITE SellNIGHTSTAR THERAPEUTICS PLCadr$25,420,000
+16.3%
1,768,946
-0.2%
0.98%
+3.4%
NewARRAY BIOPHARMA INCnote 2.625%12/0$25,196,00019,000,000
+100.0%
0.97%
ELGX SellENDOLOGIX INC$25,055,000
-21.0%
5,923,161
-0.1%
0.97%
-29.8%
IFRX SellINFLARX NV$24,546,000
+36.7%
851,100
-0.7%
0.95%
+21.4%
NewALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0$23,090,00025,000,000
+100.0%
0.89%
SYRS BuySYROS PHARMACEUTICALS INC$21,446,000
+245.9%
1,652,240
+159.3%
0.83%
+206.7%
PRAH SellPRA HEALTH SCIENCES INC$20,351,000
-10.8%
245,314
-2.1%
0.79%
-20.8%
MDRX SellALLSCRIPTS HEALTHCARE SOLUTN$20,092,000
-22.0%
1,626,900
-8.1%
0.78%
-30.7%
CMRX SellCHIMERIX INC$19,389,000
+9.3%
3,728,690
-2.7%
0.75%
-3.0%
ARGX BuyARGENX SEsponsored adr$19,193,000
+52.0%
238,600
+19.3%
0.74%
+35.0%
EHTH SellEHEALTH INC$19,039,000
-29.7%
1,330,495
-14.7%
0.74%
-37.6%
HSKA BuyHESKA CORP$18,854,000
+19.7%
238,446
+21.4%
0.73%
+6.3%
DCPH BuyDECIPHERA PHARMACEUTICALS IN$16,458,000
+12.3%
821,280
+20.1%
0.64%
-0.2%
MYL NewMYLAN N V$15,686,000381,000
+100.0%
0.61%
NLNK SellNEWLINK GENETICS CORP$14,893,000
-12.4%
2,054,200
-2.0%
0.58%
-22.2%
ODT SellODONATE THERAPEUTICS INC$12,585,000
-15.7%
594,200
-0.5%
0.49%
-25.1%
ARMO NewARMO BIOSCIENCES INC$11,178,000298,800
+100.0%
0.43%
TDOC BuyTELADOC INC$11,010,000
+110.6%
273,200
+82.1%
0.42%
+87.2%
NVTA SellINVITAE CORP$10,034,000
-50.3%
2,139,520
-3.7%
0.39%
-55.9%
CTMX SellCYTOMX THERAPEUTICS INC$9,522,000
+7.7%
334,680
-20.1%
0.37%
-4.2%
MODN SellMODEL N INC$9,457,000
-29.7%
523,937
-38.6%
0.36%
-37.6%
UHS SellUNIVERSAL HLTH SVCS INCcl b$7,993,000
-67.5%
67,500
-68.9%
0.31%
-71.1%
BGNE NewBEIGENE LTDsponsored adr$6,720,00040,000
+100.0%
0.26%
PETQ SellPETIQ INC$5,244,000
+7.0%
197,159
-12.1%
0.20%
-5.2%
LIFE SellATYR PHARMA INC$4,995,000
-24.4%
1,884,992
-0.1%
0.19%
-32.8%
ACRS SellACLARIS THERAPEUTICS INC$1,871,000
-29.1%
106,820
-0.2%
0.07%
-37.4%
OVID SellOVID THERAPEUTICS INC$1,136,000
-63.2%
160,718
-48.6%
0.04%
-67.2%
EXAS NewEXACT SCIENCES CORP$328,0008,130
+100.0%
0.01%
IHF NewISHARES TRus hlthcr pr etf$330,0002,087
+100.0%
0.01%
HZNP  HORIZON PHARMA PLC$284,000
-2.7%
20,0000.0%0.01%
-15.4%
FLXN NewFLEXION THERAPEUTICS INC$223,0009,930
+100.0%
0.01%
ARAY NewACCURAY INC$145,00029,000
+100.0%
0.01%
ADVM  ADVERUM BIOTECHNOLOGIES INC$129,000
+65.4%
22,2360.0%0.01%
+66.7%
CSLT ExitCASTLIGHT HEALTH INCcl b$0-10,229
-100.0%
-0.00%
VCRA ExitVOCERA COMMUNICATIONS INC$0-7,000
-100.0%
-0.01%
PCRX ExitPACIRA PHARMACEUTICALS INC$0-5,190
-100.0%
-0.01%
BMRN ExitBIOMARIN PHARMACEUTICAL INC$0-2,500
-100.0%
-0.01%
HUM ExitHUMANA INC$0-1,000
-100.0%
-0.01%
ALGN ExitALIGN TECHNOLOGY INC$0-1,140
-100.0%
-0.01%
NKTR ExitNEKTAR THERAPEUTICS$0-5,327
-100.0%
-0.01%
CASC ExitCASCADIAN THERAPEUTICS INC$0-649,446
-100.0%
-0.10%
PRQR ExitPROQR THRAPEUTICS N V$0-1,558,392
-100.0%
-0.22%
GMED ExitGLOBUS MED INCcl a$0-208,600
-100.0%
-0.37%
TRXC ExitTRANSENTERIX INC$0-5,017,790
-100.0%
-0.42%
ExitARRAY BIOPHARMA INCnote 2.625%12/0$0-19,000,000
-100.0%
-0.94%
CTLT ExitCATALENT INC$0-833,063
-100.0%
-1.49%
INCR ExitINC RESH HLDGS INCcl a$0-1,067,318
-100.0%
-2.02%
SGEN ExitSEATTLE GENETICS INC$0-1,156,021
-100.0%
-2.69%
CELG ExitCELGENE CORP$0-653,000
-100.0%
-2.96%
AZN ExitASTRAZENECA PLCsponsored adr$0-2,021,600
-100.0%
-3.05%
CLVS ExitCLOVIS ONCOLOGY INC$0-1,320,027
-100.0%
-3.90%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC43Q3 202310.1%
ATARA BIOTHERAPEUTICS INC36Q3 20236.4%
FATE THERAPEUTICS INC34Q3 202317.2%
INVITAE CORP32Q3 20232.7%
REGENXBIO INC28Q3 20233.8%
CLOVIS ONCOLOGY INC27Q1 20206.7%
IMMUNOGEN INC27Q3 202313.2%
CASTLIGHT HEALTH INC SAN FRAN COM STK27Q1 20212.5%
ARRAY BIOPHARMA INC26Q2 201912.6%
DECIPHERA PHARMACEUTICALS IN25Q3 20237.0%

View Redmile Group, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Redmile Group, LLC Q1 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.July 27, 20232,912,2286.6%
IGM Biosciences, Inc.June 28, 20233,291,0929.9%
MedAvail Holdings, Inc.June 21, 2023124,507,26873.1%
Achilles Therapeutics plcFebruary 14, 20231,608,0893.9%
Kymera Therapeutics, Inc.February 14, 20232,673,8374.9%
Old Ayala, IncSold outFebruary 08, 202300.0%
Zymeworks Inc.August 08, 20225,758,2419.9%
Science 37 Holdings, Inc.June 15, 202219,808,23417.1%
Allakos Inc.February 14, 20222,077,8753.8%
Aprea Therapeutics, Inc.Sold outFebruary 14, 202200.0%

View Redmile Group, LLC's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-01
42024-04-01
42024-03-25
SC 13D/A2024-03-25
42024-03-19
42024-03-14
42024-03-13
SC 13D/A2024-03-13
42024-03-05
SC 13D/A2024-03-05

View Redmile Group, LLC's complete filings history.

Compare quarters

Export Redmile Group, LLC's holdings